NS-2664
From Wikipedia, the free encyclopedia
Systematic (IUPAC) name | |
---|---|
5-furan-3-yl-1-(3-imidazol-1-yl-phenyl)-1H-benzoimidazole
|
|
Identifiers | |
PubChem | CID 9840300 |
ChemSpider | 8016018 |
Chemical data | |
Formula | C20H14N4O |
Molar mass | 326.351 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
(what is this?) (verify) |
NS-2664 (LS-193,048) is an anxiolytic drug with a novel chemical structure, developed by the small pharmaceutical company Neurosearch. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. NS-2664 is a potent but non-selective partial agonist at GABAA receptors, although with little efficacy at the α1 subtype and more at α2 and α3. It has potent anticonvulsant effects in animal studies, but a relatively short duration of action, and produces little sedative effects or physical dependence.[1]
References[edit]
- ^ Mirza NR, Nielsen EØ. Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice? Journal of Pharmacology and Experimental Therapeutics. 2006 Mar;316(3):1378-85. PMID 16352707
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |